No data to show
XOSL
NYKD
Market cap65mUSD
Apr 25, Last price
2.31NOK
1D
-6.18%
1Q
-16.98%
IPO
-96.22%
Name
Nykode Therapeutics ASA
Chart & Performance
P/E
—
P/S
7.53
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-24.98%
Rev. gr., 5y
151.20%
Revenues
9m
-32.73%
Net income
-39m
L+10.43%
CFO
-51m
L-46.99%
Earnings
May 12, 2025
Profile
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; and research agreement with Regeneron. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | 8,679 -32.73% | 12,902 -81.29% | 68,961 -76.39% | ||||||
Cost of revenue | 39,700 | 35,636 | 507,249 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (31,021) | (22,734) | (438,288) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (6,692) | (8,932) | (79,274) | ||||||
Tax Rate | |||||||||
NOPAT | (24,329) | (13,802) | (359,014) | ||||||
Net income | (38,821) 10.43% | (35,154) -91.45% | (411,216) 408.01% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 45,697 | 17,288 | |||||||
BB yield | -0.71% | -0.21% | |||||||
| Debt | |||||||||
Debt current | 1,293 | 1,457 | 11,299 | ||||||
Long-term debt | 5,583 | 9,995 | 47,365 | ||||||
Deferred revenue | 38,635 | ||||||||
Other long-term liabilities | 822 | 2 | 296 | ||||||
Net debt | (108,522) | (150,502) | (1,974,898) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (51,220) | (96,624) | (163,965) | ||||||
CAPEX | (71) | (1,902) | (25,735) | ||||||
Cash from investing activities | 6,931 | 7,040 | 70,875 | ||||||
Cash from financing activities | (1,400) | 44,589 | 3,781 | ||||||
FCF | (21,554) | 69,522 | (372,035) | ||||||
| Balance | |||||||||
Cash | 115,398 | 161,954 | 2,033,108 | ||||||
Long term investments | 453 | ||||||||
Excess cash | 114,964 | 161,309 | 2,030,114 | ||||||
Stockholders' equity | (8,395) | 29,926 | 726,029 | ||||||
Invested Capital | 148,869 | 147,061 | 874,572 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 324,400 | 300,520 | 290,119 | ||||||
Price | 3.05 -85.77% | 21.40 -23.90% | 28.12 -65.15% | ||||||
Market cap | 988,122 -84.64% | 6,431,136 -21.17% | 8,158,146 -64.70% | ||||||
EV | 879,600 | 6,280,634 | 6,183,248 | ||||||
EBITDA | (28,770) | (20,612) | (420,846) | ||||||
EV/EBITDA | |||||||||
Interest | 188 | 224 | 241 | ||||||
Interest/NOPBT | |||||||||